Generic Aplenzin Availability
Last updated on Jul 9, 2025.
Aplenzin is a brand name of bupropion, approved by the FDA in the following formulation(s):
APLENZIN (bupropion hydrobromide - tablet, extended release;oral)
-
Manufacturer: BAUSCH
Approval date: April 23, 2008
Strength(s): 174MG [RLD], 348MG [RLD], 522MG [RLD]
Is there a generic version of Aplenzin available?
No. There is currently no therapeutically equivalent version of Aplenzin available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aplenzin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Modified release formulations of a bupropion salt
Patent 7,241,805
Issued: July 10, 2007
Inventor(s): Oberegger; Werner et al.
Assignee(s): Biovail Laboratories, Inc. (Mississauga, Ontario, CA)The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Patent expiration dates:
- June 27, 2026✓
- June 27, 2026
-
Modified release formulations of a bupropion salt
Patent 7,569,610
Issued: August 4, 2009
Inventor(s): Oberegger; Werner et al.
Assignee(s): Biovail Laboratories International SRL (St. Michael, BB)The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Patent expiration dates:
- June 27, 2026✓
- June 27, 2026
-
Modified release formulations of a bupropion salt
Patent 7,572,935
Issued: August 11, 2009
Inventor(s): Oberegger; Werner et al.
Assignee(s): Biovail Laboratories International S.R.L. (St. Michael, BB)The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Patent expiration dates:
- June 27, 2026✓
- June 27, 2026
-
Modified release formulations of a bupropion salt
Patent 7,585,897
Issued: September 8, 2009
Inventor(s): Oberegger; Werner et al.
Assignee(s): Biovail Laboratories International S.r.l. (St. Michael, BB)The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Patent expiration dates:
- June 27, 2026✓
- June 27, 2026
-
Bupropion hydrobromide and therapeutic applications
Patent 7,645,802
Issued: January 12, 2010
Inventor(s): Oberegger; Werner et al.
Assignee(s): Biovail Laboratories International SRL. (St. Michael, BB)Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
Patent expiration dates:
- June 27, 2026✓
- June 27, 2026
-
Modified release formulations of a bupropion salt
Patent 7,649,019
Issued: January 19, 2010
Inventor(s): Oberegger; Werner et al.
Assignee(s): Biovail Laboratories International S.R.L. (St. Michael, BB)The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Patent expiration dates:
- June 27, 2026✓
- June 27, 2026
-
Modified release formulations of a bupropion salt
Patent 7,662,407
Issued: February 16, 2010
Inventor(s): Oberegger; Werner et al.
Assignee(s): Biovail Laboratories International S.R.L. (St. Michael, BB)The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Patent expiration dates:
- June 27, 2026✓
- June 27, 2026
-
Bupropion hydrobromide and therapeutic applications
Patent 7,671,094
Issued: March 2, 2010
Inventor(s): Williams; Robert Parry et al.
Assignee(s): Biovail Laboratories International S.R.L. (St. Michael, BB)Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
Patent expiration dates:
- June 27, 2026✓
- June 27, 2026
More about Aplenzin (bupropion)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (22)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antidepressants
- Breastfeeding
- En español
Patient resources
Other brands
Wellbutrin, Wellbutrin XL, Wellbutrin SR, Zyban, ... +4 more
Professional resources
Other brands
Wellbutrin, Wellbutrin XL, Wellbutrin SR, Zyban, Forfivo XL
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
